Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.

Shares of Bristol Myers Squibb Co. BMY rose 3.67% to $57.88 Monday, on what proved to be an all-around mixed trading session ...

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

Bristol Myers said about 5% to 7% of people with metastatic colorectal cancer have microsatellite instability-high or mismatch-repair-deficient tumors, adding that these patients are less likely to ...

In a regulatory filing on Friday night, Bristol Myers (BMY) disclosed that its CEO Christopher Boerner bought 2K shares of common stock on ...

Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...

The application was based on results from the three-arm Phase 3 CheckMate -8HW study.

The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as a first-line therapy for patients with a ...

How intelligent technologies are transforming the biopharma industry’Life-changing interventions that have previously been ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...